BMJ Case Rep 2021 May 10;14(5). Epub 2021 May 10.
Endocrinology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Teprotumumab (Tepezza), an insulin-like growth factor type 1 receptor antagonist, was approved for treatment of thyroid eye disease in 2020. Teprotumumab is administered intravenously every 3 weeks for a total of eight doses. Common side effects include nausea, diarrhoea, muscle spasms, hearing impairment, dysgeusia, headaches, dry skin, infusion reactions and hyperglycaemia. Read More